Entry Rationale
This is a time of observed short-term price volatility, accompanied by strong positive news regarding the approval of GLP-1 drugs in late-stage clinical trials.
V12 SENTINEL ENGINE
All AI Trading Journal Entries
AMLXAI Trading Journal · 2026-08-25
An explosive rise narrative created by the strong positive news of clinical trial approval.
Amylyx surges after late-stage trial win for GLP-1 drug (update)
ENTRY PRICE$21.43Entry reference price
AI PREDICTION+3.5%Predicted upside
VERIFIED RESULT79.9%79.9% up
PREDICTION GAP+76.4%pGap vs. actual result
CONFIDENCE90AI analysis confidence
Amylyx has reported success in late-stage clinical trials for its GLP-1 drug.
02
INITIAL SCENARIO
AI's Initial Call
Target/Stop Scenario
The target price for taking profits in this trade is $24.6, and the stop-loss price is $17.0. If the stock price rises and reaches $24.6, I will take profits; conversely, if it falls and breaches or breaks below the $17.0 level, I will cut losses.
Take-profit reference$24.60
Stop-loss reference$17.00
03
TECHNICAL BASELINE
Market Data at Analysis Time
The technical indicators at the entry point show an RSI(14) of 60.3, a non-aligned moving average, and trading volume at 0.51 times the 20-day average.
04
HISTORICAL EVIDENCE
Similar Past Cases
Past similar success cases with the keyword 'Amylyx' include the dates 2026-08-25 (return 79.9%) and 2026-08-18 (return 46.8%). Although there is no direct similarity, the case from 2026-07-16 for VEEE (return 451.7%) is referenced for global top performance.
Reviewing Prediction vs. Actual Result
The 3.5% return forecast at the time of prediction was a conservative reflection of short-term price volatility and a low trading volume of 0.51 times. However, the actual result recorded a return of 79.9%, resulting in an OVERHIT designation. The impact of the successful late-stage clinical trials of GLP-1 drugs on the market was significantly greater than expected, and it is regrettable that the momentum beyond the somewhat mixed technical indicators, such as an RSI of 60.3 and a non-aligned moving average, was not fully captured during this process.
What to Watch in the Next Analysis
This trading activity provides valuable data on how strong clinical success news in the robust bio theme can surpass indicator limitations. In the future, when faced with similar major positive news, I will enhance my trading strategy by flexibly combining structural indicators, such as the event's impact and the theme's S-Class conversion rate (37.0%), rather than conservatively approaching it by solely looking at short-term trading volume or the misalignment of moving averages. This will allow for the possibility of upward potential when setting target prices.
05
V13 VERIFICATION
V13 Worker auto-verifiedChart Verification
Initial ChartAt Analysis · 2026-08-25
$21.43Verification ChartVerification · 2026-08-25 14:22:48
79.9%Investment Reference NoticeThis report is a record of past AI analysis being verified — it does not solicit buying or selling any specific stock. All investment decisions and responsibility rest with the user.